It looks like your are using Internet Explorer.

Unfortunately, Internet Explorer is an outdated browser and we do not currently support it fully. You are seeing a limited view of the meeting details below.

To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Pharma’s money and resources, and their expertise in evidence generation, regulatory pathways and sales channels, have attracted many DTx companies. As a result, we have seen a lot of DTx - Pharma partnerships over recent years. However, we struggle to find clear success stories as DTx and pharma are still figuring out the right model. This often raises the question, is pharma the wrong strategy for DTx companies? Join us in a peer-to-peer discussion to deep dive into the following: 

  • Pharma companies have access to everything a DTx company could want: funding, research, and access to the market. But do these really translate into an advantage for the DTx companies? Is this a sustainable business model in the long run? 
  • Closing deals with pharma can take up to a year. But after that, things don’t get easier either. Is partnering with pharma slowing down the growth of DTx as a whole? Even though on paper pharma partnerships can benefit DTx, are they withholding DTx from its maximum potential?
  • Pharma may be the right strategy for some DTx companies. How can a DTx company know if this model fits their product and company vision? Are there any examples of DTx-Pharma partnership that clearly show this can be a sustainable and scalable route for DTx?
  • What other B2B strategies are there for DTx companies to pursue outside of pharma (for example employer, telehealth platforms, providers, insurance, etc.)? Is the B2C model the way to go for some products? How long will it take for these models to prove scalability and sustainability?

Apply to Attend

Thank you! Your submission has been received.

An invite invite link has been sent to you if you do not already have a HealthXL account.
Oops! Something went wrong while submitting the form.

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH

Join this HealthXL Event today:

Participate in this Digital Health Sprint in order to:
- Deep dive into a topic over 2 focused sessions.
- Engage with a small group of 10 global thought-leaders throughout.
- This sprint is outcome-focused: HealthXL and participants create exclusive outputs.
- Grow your network with our break out sessions.


You actively participate in this discussion. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Don't miss your opportunity to connect with senior leaders to shape the future of digital health. Because only if you are prepared now can you lead the future.

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Pharma’s money and resources, and their expertise in evidence generation, regulatory pathways and sales channels, have attracted many DTx companies. As a result, we have seen a lot of DTx - Pharma partnerships over recent years. However, we struggle to find clear success stories as DTx and pharma are still figuring out the right model. This often raises the question, is pharma the wrong strategy for DTx companies? Join us in a peer-to-peer discussion to deep dive into the following: 

  • Pharma companies have access to everything a DTx company could want: funding, research, and access to the market. But do these really translate into an advantage for the DTx companies? Is this a sustainable business model in the long run? 
  • Closing deals with pharma can take up to a year. But after that, things don’t get easier either. Is partnering with pharma slowing down the growth of DTx as a whole? Even though on paper pharma partnerships can benefit DTx, are they withholding DTx from its maximum potential?
  • Pharma may be the right strategy for some DTx companies. How can a DTx company know if this model fits their product and company vision? Are there any examples of DTx-Pharma partnership that clearly show this can be a sustainable and scalable route for DTx?
  • What other B2B strategies are there for DTx companies to pursue outside of pharma (for example employer, telehealth platforms, providers, insurance, etc.)? Is the B2C model the way to go for some products? How long will it take for these models to prove scalability and sustainability?

Participants

Participants

Eugene Borukhovich

COO & Co-Founder of YourCoach.Health

Anna-Maria Heidinger

Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH

Adriano Garcez

Strategy & Implementation, Medullan

Ashley Pippin

Director, Digital Product Delivery, Novartis

Tanja Dowe

CEO, Debiopharm Innovation Fund

Michael Pace

CEO & Founder at PalmHealth.co

Number of Participants


Up to 12
Date  
September 28, 2022
Community

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Pharma’s money and resources, and their expertise in evidence generation, regulatory pathways and sales channels, have attracted many DTx companies. As a result, we have seen a lot of DTx - Pharma partnerships over recent years. However, we struggle to find clear success stories as DTx and pharma are still figuring out the right model. This often raises the question, is pharma the wrong strategy for DTx companies? Join us in a peer-to-peer discussion to deep dive into the following: 

  • Pharma companies have access to everything a DTx company could want: funding, research, and access to the market. But do these really translate into an advantage for the DTx companies? Is this a sustainable business model in the long run? 
  • Closing deals with pharma can take up to a year. But after that, things don’t get easier either. Is partnering with pharma slowing down the growth of DTx as a whole? Even though on paper pharma partnerships can benefit DTx, are they withholding DTx from its maximum potential?
  • Pharma may be the right strategy for some DTx companies. How can a DTx company know if this model fits their product and company vision? Are there any examples of DTx-Pharma partnership that clearly show this can be a sustainable and scalable route for DTx?
  • What other B2B strategies are there for DTx companies to pursue outside of pharma (for example employer, telehealth platforms, providers, insurance, etc.)? Is the B2C model the way to go for some products? How long will it take for these models to prove scalability and sustainability?
Participate in the Meeting

HealthXL Meetings

HealthXL Digital Health Meetings connect you with senior leaders around the world to discuss, solve and support each other.

Your time is valuable. This is why each Digital Health Meeting is limited to 75 minutes - long enough for engaging discussions but short enough to fit into your busy weekly schedule.

Digital Health Meetings are fully interactive and promote conversation - be ready to talk!

Participant-Led

HealthXL Digital Health Meetings are not webinars. There is no audience, no recordings and no hiding behind a screen. Discuss, reflect and share learnings in a private but interactive group.

Developed for a Busy Schedule

No long speeches, no wait, no travel. Take a productive deep dive into different digital health topics in just 75 minutes - perfect for when you’re on a break.

A Community to connect and network

Join a community of gamechangers in digital health. With a HealthXL membership, you meet like-minded people with unique perspectives. And as a HealthXL member, you get access to regular Digital Health Meetings.

continueD learning

Stay informed on the HealthXL Communities Hub. Connect with your peers, receive notifications about the latest interactive Meetings, get curated digital health news and access industry reports, insights, shared resources and more.

Virtual Digital Health Meeting

Join from anywhere

No need for a high end laptop to display fancy 3D personas or interactive conference rooms: All you need is a working camera and an internet-ready device to join.

Apply to Attend now

The world of Digital Health in one Hub

Be ready for the future of Digital Health and join a community of passionate leaders, innovators and gamechangers. 

As a HealthXL member, you get access to a wealth of information, resources and connections. From daily curated news by our in-house expert team to industry reports each retailing at €2000 - you have the world of Digital Health right at your fingertips.

Our community is growing fast. Don’t miss out on your opportunity to lead the future.


Join the community here
Reports & Insights
Reports and insights shared by the DTx community
Curated
News
Daily DTx News Curated by our in-house experts
Lists & Dashboards
Interactive dashboards and downloadable organisation data

Your Digital Health Corner

All Posts
Commentary
August 10, 2022
Sprint: Virtual Care in Oncology: HCPs and Patient Adoption
Sprint: Virtual Care in Oncology: HCPs and Patient Adoption
Read More
Commentary
August 5, 2022
ICYMI 3 Big News Stories from July
ICYMI 3 Big News Stories from July
Read More
Commentary
August 5, 2022
Five Expert Insights from the HealthXL Community
Five Expert Insights from the HealthXL Community
Read More

Frequently Asked Questions

What is a HealthXL Digital Health Meeting?

HealthXL Digital Health Meetings are private group meetings limited to a maximum of 10 people across different demographic and stakeholder groups. They are not webinars, but participant-led group meetings to allow you to explore every facet of digital health with peers.

read more
view Less

How can I become a member of the Digital Health Community?

We invite you to create a free account on our Community Hub to have a look behind the curtains. We'd love to show you the platform in a personal call. Click here to schedule a free session with a member of our team.

read more
view Less

When can I access the Meeting recording?

Our Meetings are all about honest, open discussions. This is why we do not record our them. After each Meeting, if you were a participant, you will receive a link to the key takeaways; a short summary of the Meeting.

read more
view Less

I am participating in this meeting, but can't attend anymore. Can I cancel it?

It can always happen that you cannot attend meetings due to unforeseen reasons. Due to the small group size, even missing one person can be disruptive. We'd like to ask all participants to inform us with at least 48 hours notice or suggest a suitable replacement for themselves.

read more
view Less

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST
Digital Therapeutics (DTx)

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST
Digital Therapeutics (DTx)
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
LinkedIn Profile
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
LinkedIn Profile
Adriano Garcez
Strategy & Implementation, Medullan
LinkedIn Profile
Ashley Pippin
Director, Digital Product Delivery, Novartis
LinkedIn Profile
Tanja Dowe
CEO, Debiopharm Innovation Fund
LinkedIn Profile
Michael Pace
CEO & Founder at PalmHealth.co
LinkedIn Profile

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Pharma’s money and resources, and their expertise in evidence generation, regulatory pathways and sales channels, have attracted many DTx companies. As a result, we have seen a lot of DTx - Pharma partnerships over recent years. However, we struggle to find clear success stories as DTx and pharma are still figuring out the right model. This often raises the question, is pharma the wrong strategy for DTx companies? Join us in a peer-to-peer discussion to deep dive into the following: 

  • Pharma companies have access to everything a DTx company could want: funding, research, and access to the market. But do these really translate into an advantage for the DTx companies? Is this a sustainable business model in the long run? 
  • Closing deals with pharma can take up to a year. But after that, things don’t get easier either. Is partnering with pharma slowing down the growth of DTx as a whole? Even though on paper pharma partnerships can benefit DTx, are they withholding DTx from its maximum potential?
  • Pharma may be the right strategy for some DTx companies. How can a DTx company know if this model fits their product and company vision? Are there any examples of DTx-Pharma partnership that clearly show this can be a sustainable and scalable route for DTx?
  • What other B2B strategies are there for DTx companies to pursue outside of pharma (for example employer, telehealth platforms, providers, insurance, etc.)? Is the B2C model the way to go for some products? How long will it take for these models to prove scalability and sustainability?
When:
28th September @ 10AM GMT / 5PM AWST
Apply to attend
Registration Closed

Join this group of peers and get a feel of what it's like to belong to a community of digital health gamechangers.

All meetings are limited to 10 people to allow for honest discussions, so apply fast or become a HealthXL member and get priority access to all meetings, latest industry reports and and much more.

Frequently asked questions: 

What are HealthXL Virtual Meetings?

HealthXL Virtual Meetings are private group meetings limited to 10 people across different demographic and stakeholder groups. For 75 minutes, you take a deep dive into your chosen topic and explore it from different angles. Virtual Meetings are not webinars: There is no audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And through our Community Hub, you stay up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

How can I connect with other digital health leaders?

HealthXL brings together gamechangers of digital health to support honest discussions in small, private groups. In our Community Hub, for which you can register for free, you can follow a wide range of communities across telehealth, digital therapeutics, patient engagement and more. As a full HealthXL member, you also get access to curated news, the latest insights and an expert network to connect with. Join exclusive virtual meetings to exchange strategies, viewpoints and learnings with members from like-minded yet diverse stakeholder groups.

What are the benefits of being a HealthXL community member?

As member of HealthXL, you join a community of digital health thought leaders, innovators and game changers around the world. With your membership, you get access to hundreds of insights, reports and resources. You can browse a database with over 90k healthcare organizations and view their active strategic partnerships, commercial relationships, latest funding rounds and research. Through our in-house curated digital health newsfeed, you stay informed on the most impactful news and you can regularly meet with members to share learnings, discuss the latest developments and connect with peers of different demographical stakeholder groups. Contact us today to find out about pricing options.

Through focus groups, we bring together 6-10 thought leaders and industry stakeholders in a series of virtual meetings to collaborate around a defined topic. Each meeting gives the group the opportunity to examine, analyze and collaborate with one another around a digital health topic as well as produce a shareable result.